JP2009537608A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537608A5
JP2009537608A5 JP2009511524A JP2009511524A JP2009537608A5 JP 2009537608 A5 JP2009537608 A5 JP 2009537608A5 JP 2009511524 A JP2009511524 A JP 2009511524A JP 2009511524 A JP2009511524 A JP 2009511524A JP 2009537608 A5 JP2009537608 A5 JP 2009537608A5
Authority
JP
Japan
Prior art keywords
antibody
seq
light chain
heavy chain
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009511524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537608A (ja
JP5420399B2 (ja
Filing date
Publication date
Priority claimed from GB0610438A external-priority patent/GB0610438D0/en
Priority claimed from GB0611046A external-priority patent/GB0611046D0/en
Application filed filed Critical
Priority claimed from PCT/EP2007/055029 external-priority patent/WO2007137984A2/en
Publication of JP2009537608A publication Critical patent/JP2009537608A/ja
Publication of JP2009537608A5 publication Critical patent/JP2009537608A5/ja
Application granted granted Critical
Publication of JP5420399B2 publication Critical patent/JP5420399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009511524A 2006-05-25 2007-05-23 改変型ヒト化抗インターロイキン−18抗体 Active JP5420399B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0610438.4 2006-05-25
GB0610438A GB0610438D0 (en) 2006-05-25 2006-05-25 Immunoglobulins
GB0611046.4 2006-06-05
GB0611046A GB0611046D0 (en) 2006-06-05 2006-06-05 Immunoglobulins
PCT/EP2007/055029 WO2007137984A2 (en) 2006-05-25 2007-05-23 Modified humanised anti-interleukin-18 antibodies

Publications (3)

Publication Number Publication Date
JP2009537608A JP2009537608A (ja) 2009-10-29
JP2009537608A5 true JP2009537608A5 (enExample) 2013-07-25
JP5420399B2 JP5420399B2 (ja) 2014-02-19

Family

ID=38476914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511524A Active JP5420399B2 (ja) 2006-05-25 2007-05-23 改変型ヒト化抗インターロイキン−18抗体

Country Status (22)

Country Link
US (5) US8133978B2 (enExample)
EP (1) EP2027157B1 (enExample)
JP (1) JP5420399B2 (enExample)
KR (1) KR101416078B1 (enExample)
AR (1) AR061115A1 (enExample)
AU (1) AU2007267213B2 (enExample)
BR (1) BRPI0711908B8 (enExample)
CA (1) CA2652733C (enExample)
CR (1) CR10468A (enExample)
EA (1) EA017303B1 (enExample)
ES (1) ES2514495T3 (enExample)
IL (1) IL194995A0 (enExample)
MA (1) MA30486B1 (enExample)
MX (1) MX2008014842A (enExample)
MY (1) MY157173A (enExample)
NO (1) NO341921B1 (enExample)
NZ (1) NZ572565A (enExample)
PE (1) PE20080262A1 (enExample)
SG (1) SG172625A1 (enExample)
TW (1) TWI422387B (enExample)
WO (1) WO2007137984A2 (enExample)
ZA (1) ZA200809662B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
AU2007267213B2 (en) * 2006-05-25 2012-03-29 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2326315A1 (en) * 2008-08-18 2011-06-01 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
EP2685238B1 (en) 2008-08-27 2018-06-13 F. Hoffmann-La Roche AG Method to screen high affinity antibody
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
SG178546A1 (en) 2009-08-25 2012-03-29 Hoffmann La Roche Velocity factor
US20120308564A1 (en) * 2010-02-09 2012-12-06 Andrew Ian Bayliffe Treatment of a metabolic disorder
PH12012501991A1 (en) 2010-04-07 2017-07-26 Abbvie Inc Tnf-alpha binding proteins
EP2643352B1 (en) * 2010-11-23 2018-05-02 Glaxo Group Limited Antigen binding proteins to oncostatin m (osm)
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US20130149308A1 (en) * 2011-08-12 2013-06-13 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
ES2742413T3 (es) 2012-11-21 2020-02-14 Km Biologics Co Ltd Nuevo anticuerpo humano contra IL-18
JP2016519145A (ja) * 2013-05-15 2016-06-30 メディミューン リミテッド 組換え産生ポリペプチドの精製
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
PL3299810T3 (pl) 2015-05-19 2021-12-13 National Center Of Neurology And Psychiatry Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
WO2017076805A1 (en) * 2015-11-02 2017-05-11 Glaxosmithkline Intellectual Property Development Limited Use of an inhibitor of il18 for treatment of acute kidney injury
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Il-6阻害剤を含有する喘息の治療剤
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Il-6阻害剤及びccr2阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
TWI872251B (zh) 2020-05-29 2025-02-11 日商中外製藥股份有限公司 含有抗體製劑
IL301263A (en) 2020-11-18 2023-05-01 Novartis Ag BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY
EP4371573A4 (en) 2021-07-13 2025-08-20 National Univ Corporation Tokai National Higher Education And Research System MEDICINAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
US20240425560A1 (en) * 2021-09-29 2024-12-26 Chimera Bioengineering, Inc. IL-18 Variants and Uses Thereof
CN121586728A (zh) 2023-06-20 2026-02-27 阿波罗Ap43有限公司 用于治疗特应性皮炎的抗il-18抗体疗法
WO2025229563A1 (en) * 2024-05-03 2025-11-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating inflammatory bowel disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
ES2145004T3 (es) 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
JP2952750B2 (ja) * 1995-02-23 1999-09-27 株式会社林原生物化学研究所 モノクローナル抗体
DE69832970T2 (de) * 1997-04-07 2006-08-10 Genentech, Inc., South San Francisco Humanisierte antikörper und verfahren zu ihrer herstellung
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
NZ535299A (en) 2000-02-21 2006-06-30 Applied Research Systems Use of IL-18 inhibitors
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
TR200300478T2 (tr) * 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
AU2002224417A1 (en) 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20050074434A1 (en) 2001-02-23 2005-04-07 Tomoaki Hoshino Remedies for metabolic bone diseases
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
UA78516C2 (en) 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
CA2523912A1 (en) 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
SI1730191T1 (sl) * 2004-03-30 2011-11-30 Glaxo Group Ltd Imunoglobulin-vezavni hOSM
GB0425556D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
EP1987066B1 (en) 2006-02-22 2010-12-29 University of Zürich Methods for treating demyelinating diseases
AU2007267213B2 (en) * 2006-05-25 2012-03-29 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
EP2326315A1 (en) 2008-08-18 2011-06-01 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists

Similar Documents

Publication Publication Date Title
TWI769537B (zh) 標靶bcma的抗體、雙專一性抗體及其用途
CN108367075B (zh) 4-1bb结合蛋白及其用途
JP2022061992A5 (enExample)
Almagro et al. Humanization of antibodies
JP2015504306A5 (enExample)
JP2018183173A5 (enExample)
JP2014534242A5 (enExample)
RU2009124591A (ru) Соединения
CN114746440B (zh) 新型多肽复合物
JP2010524435A5 (enExample)
RU2004135103A (ru) Антитела, специфичные к cd22 человека, и их применения в терапии и диагностике
JP2012505654A (ja) 抗体をヒト化及び親和性成熟する方法
RU2009128064A (ru) Антитела к cd44
AU2013291937A1 (en) Antibodies to highly conserved targets
JP2022516881A5 (enExample)
RU2008137763A (ru) Связующий элемент для рецептора gm-csf
JP2023551027A5 (enExample)
CN101512008A (zh) 白介素-13结合蛋白
TW201014602A (en) Prostaglandin E2 binding proteins and uses thereof
RU2013110874A (ru) Антитела против il-18r1 и их применения
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
JP2022521705A5 (enExample)
JP2013509158A5 (enExample)
JP2023548529A5 (enExample)